

Case report: Bone involvement is rare in DLBCL. 70-year-old patient, applied to the orthopedics clinic due to knee pain. Knee prosthesis was planned. During operation suspicious nontumoral lesion with unclear borders was observed. Bone biopsy was taken from the intraoperatively detected lesion and a knee prosthesis was placed. According to PETCT and bonemarrow biopsy results, patient was diagnosed as stage 1E. Awareness of DLBCL with atypical presentation are of great importance in terms of early diagnosis

<https://doi.org/10.1016/j.htct.2021.10.1037>

PP 28

THE EFFECT OF COMORBIDITY AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MARGINAL ZONE LYMPHOMA

Esra TURAN ERKEK, Tuba TAHTALI

Kartal Dr. L.Kırdar City Hospital

Objective: Marginal zone lymphoma is a biologically and clinically heterogeneous group of indolent lymphoproliferative diseases, constituting 5-15% of all NHLs (Non-Hodgkin Lymphoma) ¹. By the World Health Organization; subgroups as extranodal marginal zone lymphoma (ENMZL, MALT lymphoma, Maltoma), nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL) constitute 70%, 20%, 10% of MZL (Marginal Zone Lymphoma) cases, respectively. **Methodology:** A total of 50 patients with a diagnosis of MZL who applied to our hospital between 2013 and 2021 were included in this retrospective study. All analyzes were performed on SPSS v21. The Kolmogorov-Smirnov test was used for normality control. Data are given as mean $\pm$ standard deviation for continuous variables and frequency for categorical variables. Survival times were calculated using the Kaplan Meier method. Cox regression analysis (enter method) was performed to identify important prognostic factors. $p < 0.05$ values were accepted as statistically significant results. **Results:** The mean age of 50 people in the study group was 62.88 ± 11.50 years and ranged from 34 to 84 years. 50% of the participants were male and 50% were female. The mean follow-up period of the patients was 51.80 ± 27.47 months. It was observed that none of the parameters measured in the study, such as age, gender, body mass index, diabetes, heart disease, thyroid diseases, non-hematological malignancies, chemotherapy, and radiotherapy intake, had an effect on survival. **Conclusion:** Age at diagnosis should be considered in risk assessment of patients with marginal zone lymphoma. It is thought that the fact that the patients are predominantly in the advanced stage MZL group, and the relatively short follow-up period compared to the indolent lymphoma group, has an effect on the absence of a determining effect of comorbid diseases on mortality. Prognostic markers determined by multicenter and detailed studies are needed to provide a better prediction.

<https://doi.org/10.1016/j.htct.2021.10.1038>

PP 29

CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX

Senem MARAL, Murat ALBAYRAK,
Berna AFACAN ÖZTÜRK, Merih REİS ARAS,
Fatma YILMAZ, Pınar Tıghoğlu,
Mesut TİĞLIOĞLU, Buğra SAĞLAM

Dışkapı Research and Training Hospital,
Department of Hematology

Objective: Chylothorax is the leakage of chylous contents into the pleural space as a result of damage to the thoracic duct. Chylous effusion is seen often unilateral but may be bilateral rarely. Etiology includes non-traumatic and traumatic causes. While sarcoidosis, amyloidosis, superior vena cava thrombosis and congenital anomalies are non-traumatic causes, non-Hodgkin lymphomas are the most common causes. Herein, we present a follicular lymphoma patient who was presented chylothorax at diagnosis. **Case report:** A 31-year-old male patient presented with fatigue, and dyspnea. On physical examination, inguinal and axillary multiple palpable lymphadenopathies (LAP) were observed, and respiratory sounds were significantly decreased on the left side. Computed tomography imaging revealed prevascular, paratracheal, subcarinal LAPs and 5 cm thick pleural effusion in the deepest part and compression atelectasis on the left. Excisional LAP biopsy revealed follicular lymphoma **Methodology:** When thoracentesis was performed and milky effusion was classified as an exudative. The high triglyceride level was consistent with a chylous effusion. After 6 cycles of R-CHOP treatment, the patient had a significant regression in the initial LAPs, while the chylous effusion persisted. When cytological examination of thoracentesis did not reveal lymphoma, the patient was followed-up. **Conclusion:** Chylothorax is associated with significant morbidity and mortality if left untreated. Control of the underlying malignancy is still the mainstay of treatment and reported as the most effective. In the literature, successful results were reported with the treatment of the underlying lymphoma. However, it is known, chylothorax may recur and patients should be followed-up closely.

<https://doi.org/10.1016/j.htct.2021.10.1039>

MYELOMA

PP 30

LENALIDOMIDE ASSOCIATED IMMUNE THROMBOCYTOPENIA: A CASE REPORT

İbrahim Halil Acar, Birol Guvenç

Çukurova University Faculty of Medicine

Objective: Autoimmune cytopenia is observed in many hematological malignancies, whereas immune thrombocytopenia is rarely observed in plasma cell dyscrasias, such as multiple myeloma. On the other hand, cytopenias secondary to myelosuppression due to lenalidomide use are frequently observed,